A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...

Climb Bio, Inc. (Nasdaq: CLYM) today announced the appointment of Douglas E. Williams, Ph.D., as Climb Bio's Chair of its Board of Directors. Dr. Williams will assume the role of Chair of the Board, ...

Following the game-changing success of Spinraza, a molecular-based therapy that was crucial in the treatment of SMA (Spinal Muscular Atrophy), which used to be one of the leading genetic killers of ...

DRI Healthcare Trust (DHTRF) reports a robust 54% increase in cash receipts and expands credit facilities, showcasing strategic growth and investment potential.

The company reported third-quarter 2024 revenues of $134 million, aligning with market expectations but showing a year-over-year decline of 7%, primarily due to decreased Spinraza royalty revenues.

Ionis Pharmaceuticals posted better-than-expected revenue in the third quarter, but faced challenges as it prepares to bring ...

Oral functions were found to be diminished in adults with spinal muscular atrophy in three out of five tests in a new study.

Analyst Terence Flynn of Morgan Stanley maintained a Buy rating on Biogen (BIIB – Research Report), retaining the price target of ...

This regimen of high dose delivers more drug in the first administration than the entire two-month loading phase of the approved SPINRAZA 12-milligram regimen. Consistent with the more rapid ...

Biogen raised its annual profit forecast on Wednesday, as new treatments and cost-cutting measures offset declining sales of ...

Its 10-K for 2019 published right at the start of the pandemic in 03/2020 was optimistic: We have three commercial medicines approved in major markets around the world, SPINRAZA, TEGSEDI and WAYLIVRA.